cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Rifki Febriansah
Contact Email
pharmrep1000@gmail.com
Phone
-
Journal Mail Official
pharmrep1000@gmail.com
Editorial Address
Jl. RS Fatmawati No 1. Pondok Labu Jakarta Selatan, 12450
Location
Unknown,
Unknown
INDONESIA
Pharmacy Reports
Published by Indonesian Young Scientist Group
ISSN : -     EISSN : 27989798     DOI : https://doi.org/10.51511/pr.2
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology
Pharmacy Reports is an open-access journal publishing peer-reviewed research in the pharmacy field, covering topics in pharmaceutics, biomedicine, pharmaceutical chemistry, bioinformatics, natural product, pharmacology and toxicology, and clinical pharmacy. Pharmacy Reports invites you to submit papers, covering topics in: pharmaceutics (pharmaceutical technology, drug delivery system), biomedicine (molecular biology, biochemistry, immunology, microbiology, biotechnology), pharmaceutical chemistry (analytical chemistry, medicinal chemistry: drug design, drug synthesis, pharmacochemistry, bioinformatic), natural product (fractionation, isolation, purification, and elucidation), pharmacology and toxicology (pharmacokinetics, toxicology), clinical pharmacy (therapeutic drug monitoring, adverse drug reaction, drug interaction), pharmaceutical industry, pharmacy education, community service related to pharmacy.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol. 3 No. 2 (2023): Pharmacy Reports" : 5 Documents clear
Characteristic and taste test of aromatherapy candle from essential oil of Cananga odorata Kumalasari, Desy; Husnayanti, Ana; Pratiwi, Auronita Puspa
Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.52

Abstract

Kenanga or ylang-ylang (Cananga odorata) is renowned in the pharmaceutical domain for its essential oil, which boasts therapeutic properties. This study aims to investigate the feasibility of utilizing C. odorata essential oil in the production of aromatherapy candles. It focuses on examining the oil’s characteristics, candle properties, and consumer preferences. The oil extraction employed the enfleurage method, while purification was achieved using a rotary evaporator. We adhered to the SNI 06-3949-1995 standards for analyzing the essential oil and the resultant candle characteristics. Consumer preferences were evaluated through surveys conducted with 30 panelists. The study’s results revealed an oil yield of 48.5%, consistent with the established standards. Optimally, the formula with 25% essential oil concentration demonstrated superior performance in aromatherapy candles, exhibiting a burn time of 8 hours, 30 minutes, and 30 seconds, and a melting point ranging from 51°C to 53°C. This concentration also elicited positive responses from participants in terms of the candles' appearance, aroma (both before and after burning), and therapeutic impact. Notably, the candles with a 25% essential oil concentration were most effective in rapidly delivering therapeutic benefits, predominantly inducing relaxation. The study concludes that ylang-ylang essential oil is highly promising for aromatherapy candle production, with the 25% concentration formula demonstrating optimal results in terms of standard compliance, burn time, and user satisfaction.
Comparative in-silico analysis of vitexin and orientin as potential antiphotoaging agents against MMP enzymes Nyunda, Ricky Putra Banyim; Wiantini, Ni Made Rita; Susanti, Ni Made Pitri; Laksmiani, Ni Putu Linda
Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.60

Abstract

Photoaging, a result of excessive UV exposure, increases ROS production and collagen degradation by MMPs, causing skin wrinkles and roughness. This study explores the potential of vitexin and orientin as natural antiphotoaging agents through in-silico molecular docking, comparing their efficacy against retinol in inhibiting MMP-1, MMP-3, and MMP-9 enzymes involved in photoaging. The research utilized Hyperchem 8 for compound optimization, Chimera 1.11 for target protein preparation, and AutodockTools 1.5.6 for docking analysis. Results demonstrated that vitexin and orientin exhibit stronger affinity towards MMP-1, MMP-3, and MMP-9, indicated by more negative binding energies than retinol. Their interaction with the MMP enzymes, characterized by specific hydrogen bonds with key amino acid residues, suggests a potent inhibitory effect. This affinity indicates vitexin and orientin’s potential as effective antiphotoaging agents, providing a basis for further exploration in skin care applications.
Exploring the anticancer potential of scopoletin against HER-2 positive breast cancer: an in silico molecular docking study Adhyaksa, I Nyoman Mahesa Praba; Silawarti, Putu Ayu Karunia; Putra, Made Ferdio Amarta; Laksmiani, Ni Putu Linda
Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.63

Abstract

Cancer, defined by the unchecked growth and invasive potential of abnormal cells, remains a global health challenge. Within this context, scopoletin, a compound isolated from the leaves of Impatiens balsamina L., has garnered attention for its potential as an anti-breast cancer agent. This study employed in silico molecular docking techniques to explore scopoletin's interaction with the HER-2 protein, a known target in breast cancer therapy. The docking analysis revealed that scopoletin exhibits affinity towards the HER-2 protein, with a binding energy of -6.3 kcal/mol. Notably, the binding energy of scopoletin is comparable to that of gefitinib, an established cancer drug, further underscoring its potential therapeutic value.
Molecular docking analysis of acetogenin and procyanidin, components of soursop (Annona muricata Linn.) seed, as potential anti-cervical cancer agents Pravita, Nabila Cahya; Fazilla, Rizki Fakhri; Febrian, Tobi; Mellina, Echa Dian; Kumara, Gusti Made Bagus; Nugraha, Muhammad Aditya; Vernanda, Pramyudha; Auli, Winni Nur; Saputro, Anjar Hermadi
Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.71

Abstract

Cervical cancer is one of the most prevalent cancers among women. This study aimed to investigate the molecular interactions of acetogenin and procyanidin, compounds found in soursop (Annona muricata Linn.) seed extract, as potential anti-cervical cancer agents using a molecular docking approach. The software tools used included Biovia Discovery Studio® 2024, Autodock Tools 1.5.6, Avogadro, pkCSM, PubChem, Notepad++, and Molview. Molecular docking analysis focused on the interaction of these compounds with the human vaccinia-related kinase 2 (VRK-2) protein (PDB ID: 5UU1). The native ligand-5UU1 protein complex exhibited two hydrogen bonds, a binding free energy of -8.84 kcal/mol, and an inhibition constant of 331.88 nM. In comparison, acetogenin formed three hydrogen bonds with 5UU1, achieving a binding free energy of -7.33 kcal/mol and an inhibition constant of 4.21 nM. Similarly, procyanidin also formed three hydrogen bonds, with a binding free energy of -2.99 kcal/mol and an inhibition constant of 6.38 nM. The results indicate that both acetogenin and procyanidin have potential as anti-cervical cancer agents, with acetogenin demonstrating stronger binding affinity and inhibition potential compared to procyanidin.
Exploring the anti-diabetic potential of stevia-derived compounds through PPAR-γ targeted molecular docking Putri, Amalia Sonita; Prawicha, Ertika Agtha; Putri, Esterike Alfatien; Wulandari, Indah; Saputri, Mutiara Anggun; Syakilla, Nadia Nur; Hidayati, Putri Aulia Nurul; Auli, Winni Nur; Saputro, Anjar Hermadi
Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.78

Abstract

This study explores the potential of Stevia rebaudiana Bertoni-derived compounds as anti-diabetic agents by targeting the peroxisome proliferator-activated receptor gamma (PPAR-γ), a key regulator of glucose metabolism. Utilizing in silico molecular docking, we evaluated the binding affinities of four stevia-derived compounds (dulcoside A, steviol, isosteviol, steviolmonoside) and compared them to the native ligand (J35) and the well-known PPAR-γ agonist, rosiglitazone. Isosteviol exhibited the strongest binding affinity to PPAR-γ, with a binding energy of -8.89 kcal/mol, surpassing that of rosiglitazone (-8.26 kcal/mol) and closely following the native ligand (-9.01 kcal/mol). The interactions between isosteviol and PPAR-γ included multiple hydrogen bonds and hydrophobic interactions. These findings indicate that isosteviol, along with other stevia-derived compounds, has a potential as a natural anti-diabetic agent.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2023 2023


Reset
Filter By Issues
All Issue Vol. 5 No. 3 (2025): Pharmacy Reports Vol. 5 No. 2 (2025): Pharmacy Reports Vol. 5 No. 1 (2025): Pharmacy Reports Vol. 4 No. 3 (2024): Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports Vol. 4 No. 1 (2024): Pharmacy Reports Vol. 3 No. 3 (2023): Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports Vol. 3 No. 1 (2023): Pharmacy Reports Vol. 2 No. 3 (2022): Pharmacy Reports Vol. 2 No. 2 (2022): Pharmacy Reports Vol. 2 No. 1 (2022): Pharmacy Reports Vol. 1 No. 2 (2021): Pharmacy Reports Vol. 1 No. 1 (2021): Pharmacy Reports More Issue